ArticleInternational journal of oncology2020

TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis.

Liping Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.